« Return to News | CROs/Service Providers

Cedarburg Hauser adds plant capacity

Wednesday, September 26, 2012 09:32 AM

Cedarburg Hauser Pharmaceuticals (CHP), a Grafton, Wisc.-based contract development and manufacturing organization, has expanded the capacity of its active pharmaceutical ingredient (API) manufacturing plant in Wisconsin.

The expansion efforts are a result of an increased demand for contract manufacturing of commercial APIs and are accompanied by additional upgrades aimed at improving safety and GMP systems.

“These improvements increase our total reactor capacity by nearly 50%,” said John Flahive, CHP’s newly hired director of operations. “We have also added a reactor and chiller that allow for cryogenic reactions in our GMP labs.”

In addition to the new reactors, CHP has also made improvements to the air handling systems in the GMP manufacturing suites, installed a reverse osmosis water system, improved isolation capabilities and upgraded their Emerson DeltaV Digital Automation System.

“The added reactor capacity and upgrades to existing safety and GMP systems are the latest example of Cedarburg Hauser’s continued commitment to serving the commercial API marketplace,” said Tony Laughrey, CEO of CHP. “The flexibility afforded by the additional reactor capacity allows us to better meet our customer’s on-time and on-budget requirements.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.